Randomised controlled trial to compare the efficacy of tablet Minoxidil 1.25mg Vs tablet minoxidil 2.5mg Vs topical 5% minoxidil solution in Male Pattern Hair Loss.

Randomised controlled trial to compare the efficacy of oral Minoxidil 1.25mg Vs 2.5mg Vs topical 5% minoxidil in Androgenetic Alopecia.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048560

Enrollment

Registered

2022-12-28

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: tab minoxidil 1.25mg : Oral minoxidil in dose of 1.25mg every night for 6 months Intervention2: Tab minoxidil 2.5mg: Oral minoxidil in dose 2.5mg every night for 6 months Control Interv

Eligibility

Inclusion criteria

Inclusion criteria: Male patients of age group 20-45 years clinically diagnosed with androgenetic alopecia of all grades Male patients who are willing to participate in the study and gave consent for intake of oral minoxidil in 1.25 mg and 2.5 mg doses

Exclusion criteria

Exclusion criteria: 1. Patients whose BP is lower than 100/60 mmHg. 2.Patients who have taken treatment for androgenetic alopecia in the previous 3 months. 3. Patients who are on other medications that reduce the blood pressure. 4.Patients diagnosed with pheochromocytoma, pulmonary hypertension, severe hepatic dysfunction, angina or recent myocardial infarction. 5.Patients having hypersensitivity to minoxidil.

Design outcomes

Primary

Measure	Time frame
target hair count per cm2Timepoint: baseline, 2nd month, 4th month , 6th month	—

Secondary

Measure	Time frame
photographic assessment male hair growth questionnaireTimepoint: 6 months 6 months	—

Countries

India

Contacts

Public ContactBhumika Mahawar

Mahatma Gandhi Mission Medical College and Hospita,Aurangabad

ashish7557@gmail.com9422213292

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026